Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of CYP2C8 genotypes in dose requirement and levels of everolimus after heart transplantation.

Wiener klinische Wochenschrift - 1 Jul 2013

Kniepeiss Daniela, Wagner Doris, Wasler Andrä, Tscheliessnigg Karl-Heinz, Renner Wilfried

Abstract excerpt

Everolimus is an immunosuppressive drug metabolized by enzymes of the CYP family. A common variant of the CYP2C8 gene, CYP2C8*3, results in strongly decreased CYP2C8 activity, but its role for the pharmacogenetics of everolimus remains unclear. Aim of the present study was to examine the role of CYP2C8 variants in everolimus dose and drug levels after heart transplantation. The present study comprised 30 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C8

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Everolimus

Share to Graft Rejection

Share to Heart Transplantation

Share to Immunosuppressive Agents

Share to Pharmacogenetics

Share to Sirolimus

Source

Identifiers

PMID: 23797529
DOI: 10.1007/s00508-013-0387-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

The role of CYP2C8 genotypes in dose requirement and levels of everolimus after heart transplantation.PMID 23797529Read ↗

The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.Semantic proximity Read ↗

The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients.Semantic proximity Read ↗

Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.Semantic proximity Read ↗

CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.Semantic proximity Read ↗

Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy.Semantic proximity Read ↗

Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients.Semantic proximity Read ↗

Effect of fluconazole on the pharmacokinetics of everolimus and tacrolimus in a heart transplant recipient: Case report.Semantic proximity Read ↗

CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.